HomeCompareEPGNF vs SBUX

EPGNF vs SBUX: Dividend Comparison 2026

EPGNF yields 178.57% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPGNF wins by $62.76M in total portfolio value
10 years
EPGNF
EPGNF
● Live price
178.57%
Share price
$1.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62.91M
Annual income
$29,936,192.20
Full EPGNF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — EPGNF vs SBUX

📍 EPGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPGNFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPGNF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPGNF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPGNF
Annual income on $10K today (after 15% tax)
$15,178.57/yr
After 10yr DRIP, annual income (after tax)
$25,445,763.37/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, EPGNF beats the other by $25,389,799.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPGNF + SBUX for your $10,000?

EPGNF: 50%SBUX: 50%
100% SBUX50/50100% EPGNF
Portfolio after 10yr
$31.54M
Annual income
$15,001,016.16/yr
Blended yield
47.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

EPGNF
No analyst data
Altman Z
-10.1
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPGNF buys
0
SBUX buys
6
PoliticianChamberTickerTypeAmountDate
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Dan Newhouse🏢 House$SBUX▼ Sell$1,001 - $15,0002025-12-11
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$SBUX▲ Buy$15,001 - $50,0002025-09-29
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-08-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPGNFSBUX
Forward yield178.57%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$62.91M$157.5K
Annual income after 10y$29,936,192.20$65,840.13
Total dividends collected$58.90M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: EPGNF vs SBUX ($10,000, DRIP)

YearEPGNF PortfolioEPGNF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$28,557$17,857.14$11,107$407.21+$17.4KEPGNF
2$78,215$47,658.78$12,512$626.87+$65.7KEPGNF
3$205,683$121,992.76$14,366$978.69+$191.3KEPGNF
4$519,899$299,818.53$16,929$1,557.50+$503.0KEPGNF
5$1,264,557$708,265.17$20,658$2,543.80+$1.24MEPGNF
6$2,963,097$1,610,021.03$26,406$4,302.22+$2.94MEPGNF
7$6,696,294$3,525,779.94$35,877$7,622.00+$6.66MEPGNF
8$14,611,669$7,446,634.50$52,741$14,352.64+$14.56MEPGNF
9$30,820,422$15,185,936.42$85,676$29,243.03+$30.73MEPGNF
10$62,914,044$29,936,192.20$157,513$65,840.13+$62.76MEPGNF

EPGNF vs SBUX: Complete Analysis 2026

EPGNFStock

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Full EPGNF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this EPGNF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPGNF vs SCHDEPGNF vs JEPIEPGNF vs OEPGNF vs KOEPGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.